NJK14047
Chemical compound
| NJK14047 | |
|---|---|
| |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
NJK14047 is a chemical compound that has been studied for its potential therapeutic effects, particularly in the context of neurodegenerative diseases. It is known for its role as a modulator of neurotrophic factors, which are crucial for the survival, development, and function of neurons.
Chemical Structure[edit]
NJK14047 is characterized by its complex molecular structure, which includes a piperazine ring and a trifluoromethyl group. The presence of these functional groups is significant for its biological activity, influencing its interaction with various biological targets.
Mechanism of Action[edit]
NJK14047 functions primarily by modulating the activity of neurotrophic factors. These factors, such as nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF), play a pivotal role in neuronal health. By influencing these pathways, NJK14047 may help in promoting neuronal survival and regeneration, which is particularly beneficial in conditions like Alzheimer's disease and Parkinson's disease.
Potential Therapeutic Applications[edit]
The primary interest in NJK14047 lies in its potential application in treating neurodegenerative disorders. By enhancing the activity of neurotrophic factors, NJK14047 could potentially slow down or reverse the progression of diseases characterized by neuronal loss. Research is ongoing to determine its efficacy and safety in clinical settings.
Pharmacokinetics[edit]
The pharmacokinetic profile of NJK14047 is still under investigation. Understanding its absorption, distribution, metabolism, and excretion (ADME) is crucial for developing it as a therapeutic agent. Preliminary studies suggest that it has a favorable profile, but more research is needed to confirm these findings.
Safety and Efficacy[edit]
As with any potential therapeutic compound, the safety and efficacy of NJK14047 must be thoroughly evaluated through clinical trials. Initial studies have shown promise, but comprehensive trials are necessary to establish its therapeutic value and safety profile.
Related Pages[edit]
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa
Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
